Cargando…

Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

The liver plays a central role in the pharmacokinetics of drugs through drug metabolizing enzymes and transporters. Non-alcoholic steatohepatitis (NASH) causes disease-specific alterations to the absorption, distribution, metabolism, and excretion (ADME) processes, including a decrease in protein ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marie, Solène, Frost, Kayla L., Hau, Raymond K., Martinez-Guerrero, Lucy, Izu, Jailyn M., Myers, Cassandra M., Wright, Stephen H., Cherrington, Nathan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939324/ https://www.ncbi.nlm.nih.gov/pubmed/36815037 http://dx.doi.org/10.1016/j.apsb.2022.08.018

Ejemplares similares

Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity
por: Jilek, Joseph L., et al.
Publicado: (2021)

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients
por: Hau, Raymond K., et al.
Publicado: (2022)

Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug
por: Guo, Jing, et al.
Publicado: (2021)

Systems Level Metabolic Phenotype of Methotrexate Administration in the Context of Non-alcoholic Steatohepatitis in the Rat
por: Kyriakides, Michael, et al.
Publicado: (2014)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis
por: Clarke, John D., et al.
Publicado: (2015)

Generation of a hTERT-Immortalized Human Sertoli Cell Model to Study Transporter Dynamics at the Blood-Testis Barrier
por: Hau, Raymond K., et al.
Publicado: (2020)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

Sex differences in pharmacokinetics predict adverse drug reactions in women
por: Zucker, Irving, et al.
Publicado: (2020)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2023)

Nitro-oleic acid as a new drug candidate for non-alcoholic steatohepatitis
por: Yang, Rui-Xu, et al.
Publicado: (2019)

New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis
por: Stojsavljevic-Shapeski, Sanja, et al.
Publicado: (2021)

Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis
por: Diesinger, Torsten, et al.
Publicado: (2020)

Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients
por: Sternieri, E., et al.
Publicado: (2005)

Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management
por: Li, Wei, et al.
Publicado: (2013)

Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside
por: Assmus, Frauke, et al.
Publicado: (2022)

Preventable adverse drug events: Descriptive epidemiology
por: Woo, Stephanie A., et al.
Publicado: (2020)

The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori
por: Lecube, Albert, et al.
Publicado: (2016)

Correction: Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis
Publicado: (2021)

ω‐Imidazolyl‐alkyl derivatives as new preclinical drug candidates for treating non‐alcoholic steatohepatitis
por: Diesinger, Torsten, et al.
Publicado: (2021)

A novel diet‐induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis
por: Ejima, Chieko, et al.
Publicado: (2016)

Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease
por: Rabinowich, Liane, et al.
Publicado: (2015)

Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review
por: Ghasemiyeh, Parisa, et al.
Publicado: (2020)

Pharmacokinetic Drug–Drug Interactions and Herb–Drug Interactions
por: Choi, Min-Koo, et al.
Publicado: (2021)

Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
por: Mouries, Juliette, et al.
Publicado: (2019)

Drug Metabolism and Pharmacokinetics
Publicado: (2008)

Nonalcoholic Steatohepatitis Disrupts Diurnal Liver Transcriptome Rhythms in Mice
por: de Assis, Leonardo Vinicius Monteiro, et al.
Publicado: (2023)

Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update
por: Di Pasqua, Laura Giuseppina, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
por: Chen, Yuan, et al.
Publicado: (2020)

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
por: Shnayder, Natalia A., et al.
Publicado: (2021)

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials
por: Mocquot, Pauline, et al.
Publicado: (2022)

Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis
por: Lan, Tian, et al.
Publicado: (2022)

Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults
por: Pierre, V, et al.
Publicado: (2017)

Mining drug–target and drug–adverse drug reaction databases to identify target–adverse drug reaction relationships
por: Galletti, Cristiano, et al.
Publicado: (2021)

Drug–drug–gene interactions and adverse drug reactions
por: Malki, Mustafa Adnan, et al.
Publicado: (2019)

Transporter Inhibition Profile for the Antivirals Tilorone, Quinacrine and Pyronaridine
por: Vignaux, Patricia A., et al.
Publicado: (2023)

Hydroxynonenal Causes Hepatocyte Death by Disrupting Lysosomal Integrity in Nonalcoholic Steatohepatitis
por: Seike, Takuya, et al.
Publicado: (2022)

Pharmacokinetic drug-drug interaction and their implication in clinical management
por: Palleria, Caterina, et al.
Publicado: (2013)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ngftb889f6lg622aklqqh91pli